Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Bon

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Neoplasia (New York, N.Y.)|September 28, 2023
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP studyGiulia Bon, Eriseld Krasniqi, Manuela Porru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with ImmunotherapyStefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
Experimental and Molecular Pathology|May 28, 2026
Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049]Stefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Experimental and Molecular Pathology|May 11, 2026
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinomaStefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Neoplasia (New York, N.Y.)|September 28, 2023
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP studyGiulia Bon, Eriseld Krasniqi, Manuela Porru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with ImmunotherapyStefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
Experimental and Molecular Pathology|May 28, 2026
Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049]Stefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Experimental and Molecular Pathology|May 11, 2026
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinomaStefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Pageof 3